Makes ready-to-use injectable and delivery technologies for hormone deficiency and endocrine drugs.
Makes ready-to-use injectable and delivery technologies for hormone deficiency and endocrine drugs.
Earns from selling three branded drugs in the US, mostly through wholesalers and pharmacies, with insurers deciding coverage. Gvoke serves diabetes, a large patient group, while Recorlev and Keveyis treat rare conditions with few prescribers. The 2021 merger with Strongbridge Biopharma brought in the two rare-disease drugs.
Moat: narrow (IP / patents, process know-how). Proprietary non-aqueous formulation technology avoids the reconstitution steps needed by rival products.
Headquarters: Chicago, Illinois, US · Founded: 2005 · Employees: 435
Size Xeris Biopharma (XERS) is a United States Health Care company (Biotechnology) with a market value of $3.10B, the 1515th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.99 on 18 Nov 2026.
Performance Over six months the shares gained 172.7%, against +2.8% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 38.4% over the last twelve months (peer median +6.3%); the operating margin is 12.7% (peer median -31.7%).
Valuation It trades at 49.7× forward earnings against a peer median of 26.7× (2nd most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +70%, so the hurdle is -41 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 16.8 points above its cost of capital (8.9% WACC).
Backlog Backlog (remaining performance obligations) was $6.20M at 30 Sep 2026 — 0.0 years of trailing revenue. Backlog detail →
Short interest Short interest is 4.9% of the free float (30 Oct 2026).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $368M | $292M | $203M | $164M | $110M |
| Revenue growth | — | +44% | +24% | +49% | — |
| Gross profit | $311M | $238M | $155M | $124M | $76.8M |
| EBITDA | $59.6M | $37.6M | -$21.0M | -$30.9M | -$67.8M |
| Net income | -$6.50M | $554,000 | -$54.8M | -$62.3M | -$94.7M |
| Free cash flow | $72.6M | $27.9M | -$37.8M | -$50.5M | -$103M |
| Capital expenditure | $1.03M | $696,000 | $868,000 | $2.26M | $524,000 |
| Total debt | $226M | $258M | $271M | $229M | $198M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Xeris Biopharma XERS | $3.10B | +173% | +38% | 13% | 49.7× | 29.5% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 11.8× | -0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | XERS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +52.6% | -4.6% | highest of 21 |
| 6-month return | +172.7% | +2.8% | highest of 21 |
| Distance from 52-week high | -1.7% | -27.8% | highest of 21 |
| Revenue growth (TTM) | +38.4% | +6.3% | 3rd highest of 16 |
| Operating margin | 12.7% | -31.7% | 7th highest of 17 |
| Forward P/E | 49.7× | 26.7× | 2nd most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 29.5% | 2.2% | most demanding of 6 |
| Growth delivered (Del g) | +70.2% | +12.5% | highest of 6 |
| Hurdle (Req g minus delivered) | -40.7 pp | -10.3 pp | 2nd least demanding of 6 |
| ROIC minus cost of capital | +16.8 pp | -9.4 pp | 2nd highest of 16 |
| EV / EBITDA | 53.7× | 12.8× | 3rd most expensive of 6 |
| Net debt / EBITDA | 1.6× | 0.5× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 49.7× | 29.5% | +70.2% |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 16.6× | 5.8% | +9.4% |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 26.7× | 15.8% | -1.8% |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 16.7× | -0.8% | +64.6% |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 34.5× | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | n/a | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 66.6× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | n/a | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | n/a | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 16.6× | -4.3% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 33.1× | 2.2% | +12.5% |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | n/a | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| HLB 028300.KS | South Korea | $2.69B | -49% | +26% | -96% | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | n/a | n/a | n/a |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | n/a | n/a | n/a |
Xeris Biopharma reported $6.20M of remaining performance obligations at 30 Sep 2026 and up 24% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.01.